Adial Pharmaceuticals ADILW 深 沪
等待开盘 04-03 09:30:00 美东时间
0.0009
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0009
- 总市值 1.58万
- 52周最高 0.199
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0004
- 委 比 0.00%
- 总股本 1750.35万
- 历史最高 2.45
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder
Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.
03-24 21:13
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
U.S. Congress has introduced H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act, to expand research and development of therapies for conditions affecting U.S. veterans, including Alcohol Use Disorder (AUD). The bill aligns with updated federal recovery standards, supporting non-abstinence-based treatments. Adial Pharmaceuticals, Inc. commends this bipartisan legislation, noting its potential to advance therapies like their inves...
03-24 13:07
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(11.48) per share which missed the analyst consensus estimate of $(0.09) by 12655.56 percent. This is a 206.13 percent decrease over losses of $(3.75) per
03-06 21:07
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization
An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. On Mar...
03-03 21:48
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million
Adial Pharma signs Europe deal with Molteni for AD04, eyeing up to $60 million in milestones and royalties.
03-03 21:02
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program
Adial Pharmaceuticals ( ($ADIL) ) has shared an update. Adial Pharmaceuticals, ...
02-24 22:51
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Adial Pharmaceuticals regained NASDAQ compliance after meeting the minimum bid price requirement. CEO Cary Claiborne emphasized this as a key milestone toward advancing AD04, a potential AUD treatment, into Phase 3 trials. The company is in advanced discussions with strategic partners for AD04's development and commercialization. AD04 also shows promise for treating other addictive disorders.
02-24 14:00
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Adial Pharmaceuticals (NASDAQ: ADIL) announced that CEO Cary Claiborne will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Feb. 25, 2026. The presentation will be webcast live and available on the company's investor relations website. Adial, a clinical-stage biopharmaceutical company focused on developing treatments for addictions, highlighted its lead product AD04, which showed promising results in reducing drinkin...
02-17 14:00
Adial Pharmaceuticals Announces 1-For-25 Reverse Stock Split, Effective Feb. 5
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,
02-04 05:23
Adial Pharmaceuticals Announces 1-for-25 Reverse Stock Split
Adial Pharmaceuticals Announces 1-for-25 Reverse Stock Split Adial Pharmaceuticals Inc. has announced a 1-for-25 reverse stock split of its common stock, effective February 5, 2026. The company's shares will continue to trade on the Nasdaq Capital Market under the symbol "ADIL" on a split-adjusted b
02-04 05:07
